Last updated on November 2017

CTSU/ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High-Risk Melanoma


Brief description of study

CTSU/ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High-Risk Melanoma

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01274338?term=E1609&rank=1

Clinical Study Identifier: TX13392

Contact Investigators or Research Sites near you

Start Over

Patricia Green

Memorial Health University Medical Center
Savannah, GA USA